Astellas Signs a License Agreement with ExCellThera for In Vitro Use of UM171 in Pluripotent Stem Cells

Shots:

  • ExCellThera to receive up front, future contingent payments along with manufacturing and supply fees for the licensed molecules
  • The collaboration validates the immense clinical and commercial potential of UM171 in additional fields of development
  • The collaboration allows the ExcelThera to focus on clinical programs and commercial plans for ECT-001 cell therapy product along with cell expansion and rejuvenation platform & other pre/clinical areas of interest

Click here to read full press release/ article | Ref: Globe Newswire | Image: HRI Portal

The post Astellas Signs a License Agreement with ExCellThera for In Vitro Use of UM171 in Pluripotent Stem Cells first appeared on PharmaShots.